title: Factor VIII recovery after a single infusion of recalibrated ReFacto in 14 severe haemophilia A patients.
abstract: A recent multicentre collaborative study showed higher estimates of ReFacto potency when assayed with ReFacto Laboratory Standard(TM) (RLS) in comparison when standards consisting of full-length factor VIII (FVIII) were used. The RLS was hence recalibrated, leading to a 20% increase in the amount of ReFacto per vial without change in the labelled potency. The primary objective of this study was to determine the incremental and in vivo recovery of the recalibrated ReFacto in patients with severe haemophilia A. Fourteen male severe haemophilia A patients (FVIII < 1 IU dL(-1)) with a cumulative previous exposure days to any FVIII product >150 were administered an intravenous infusion 50 +/- 5 IU kg(-1) of ReFacto over a 5-min period. Blood samples were collected before infusion and after 15, 30 and 60 min. FVIII clotting activity (FVIII:C) was assessed in a central laboratory by the chromogenic substrate assay. After ReFacto infusion, peak FVIII:C was obtained within 15 min for 10 patients and within 30 min for the remaining four. Mean FVIII:C at peak was 117.7 +/- 17.3 IU dL(-1). Mean incremental recovery was 2.22 +/- 0.27 IU dL(-1) per IU kg(-1) while mean in vivo recovery was 105.9 +/- 14.6%. One patient reported three mild adverse events rated as 'unrelated' to the study drug. FVIII recovery after recalibrated ReFacto infusion falls within the expected range and is similar to the values reported for other FVIII concentrates.
authors.affiliation: CHU Bicêtre AP-HP, Le Kremlin Bicêtre, France. thierry.lambert@bct.aphp.fr
authors.forename: T
authors.initials: T
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Guérois
authors.forename: V
authors.initials: V
authors.lastname: Gay
authors.forename: N
authors.initials: N
authors.lastname: Stieltjes
authors.forename: M-A
authors.initials: MA
authors.lastname: Bertrand
authors.forename: A
authors.initials: A
authors.lastname: Derlon
authors.forename: M
authors.initials: M
authors.lastname: Sigaud
authors.forename: A
authors.initials: A
authors.lastname: Hassoun
authors.forename: C
authors.initials: C
authors.lastname: Négrier
authors.forename: B
authors.initials: B
authors.lastname: Coatmelec
authors.forename: M
authors.initials: M
authors.lastname: Dreyfus
authors.forename: A
authors.initials: A
authors.lastname: Dubanchet
mesh_terms: D000293:Adolescent; D000328:Adult; D019774:Blood Coagulation Factor Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002648:Child; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D012015:Reference Standards; D013810:Therapeutic Equivalency
chemical_list: D019774:Blood Coagulation Factor Inhibitors; C078147:F8 protein, human; D005169:Factor VIII